109 related articles for article (PubMed ID: 12930424)
1. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Yahara J; Noguchi M; Noda S
BJU Int; 2003 Sep; 92(4):379-83; discussion 383-4. PubMed ID: 12930424
[TBL] [Abstract][Full Text] [Related]
2. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.
Noguchi M; Kikuchi H; Ishibashi M; Noda S
Br J Cancer; 2003 Jan; 88(2):195-201. PubMed ID: 12610502
[TBL] [Abstract][Full Text] [Related]
3. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
4. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
7. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?
Yap BK; Choo R; Deboer G; Klotz L; Danjoux C; Morton G
BJU Int; 2003 May; 91(7):613-7. PubMed ID: 12699470
[TBL] [Abstract][Full Text] [Related]
8. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Haukaas S; Roervik J; Halvorsen OJ; Foelling M
Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
[TBL] [Abstract][Full Text] [Related]
9. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
11. The CT flare response of metastatic bone disease in prostate cancer.
Messiou C; Cook G; Reid AH; Attard G; Dearnaley D; de Bono JS; de Souza NM
Acta Radiol; 2011 Jun; 52(5):557-61. PubMed ID: 21498309
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between extent of bone metastases and effect of endocrine therapy evaluated with bone scintigraphy in stage D2 prostatic cancer].
Tanaka M; Murakami S; Akimoto S; Masai M; Shimazaki J
Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1036-42. PubMed ID: 1507721
[TBL] [Abstract][Full Text] [Related]
13. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
Pollen JJ; Witztum KF; Ashburn WL
AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
[TBL] [Abstract][Full Text] [Related]
14. Bone metastases from poorly differentiated adenocarcinoma of the prostate diagnosed by In-111 ProstaScint (Capromab Pendetide) images with negative results of Tc-99m MDP bone scan and without significant elevation of prostate-specific antigen.
Norris S; Halkar R; Galt J; Petros J; Keller J
Clin Nucl Med; 1999 Nov; 24(11):905-7. PubMed ID: 10551485
[No Abstract] [Full Text] [Related]
15. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
[TBL] [Abstract][Full Text] [Related]
17. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
Caglar M; Tuncel M
Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
[No Abstract] [Full Text] [Related]
18. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.
Imbriaco M; Larson SM; Yeung HW; Mawlawi OR; Erdi Y; Venkatraman ES; Scher HI
Clin Cancer Res; 1998 Jul; 4(7):1765-72. PubMed ID: 9676853
[TBL] [Abstract][Full Text] [Related]
19. [Intraoperative scintigraphic visualization of a single rib metastasis from operated prostatic adenocarcinoma].
Sanjurjo S; Hamida W; Letesson G; Hustinx R; Gillet P; Andrianne R
Prog Urol; 2008 Jun; 18(6):402-5. PubMed ID: 18558331
[TBL] [Abstract][Full Text] [Related]
20. Extensive bone metastases in a patient with prostatic adenocarcinoma and normal serum prostate-specific antigen and prostatic acid phosphatase.
Yuksel M; Cermik TF; Kaya M; Salan A; Ustun F; Salihoglu YS; Yigitbasi ON; Berkarda S
Clin Nucl Med; 2001 Nov; 26(11):962. PubMed ID: 11595863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
